

SWISS BIOTECH SUCCESS STORY



Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is born from vertical integration from Vifor Pharma and Fresenius Medical care, the largest dialysis service provider globally

VFMCRP has set the base for the transformation of Vifor Pharma to a global nephrology company


With IPO of Galenica Santé in 2018, Vifor Pharma becomes a public, Swiss based pharmaceutical company

Joint company generates real life data to support clinical trials, facilitate market access and enable an integrated disease management




KNOWLEDGE

A focused product portfolio in the field of iron deficiency, nephrology and cardio-renal therapies



INDICATIONS

Portfolio focused on anemia/iron deficiency, mineral and bone disease, cardio-renal therapies and rare renal diseases



IN-LICENSING AGREEMENTS & PIPELINE

Mircera, a long acting ESA, from Roche for the US

Veltassa, a potassium binder for treatment of hyperkalemia, from Relypsa outside the US and Japan


Rayaldee, a modified release calcifediol to treat SHPT in CKD patients from Opko Health

Epoetin zeta, a short acting ESA biosimilar, from Pfizer

Vadadustat, an HIF-PH inhibitor for renal anemia, from Akebia

Avacopan and CCX-140, targeting several rare renal diseases, both from Chemocentryx

A comprehensive pipeline targeting the nephrology, mineral and bone disease and cardio-renal space



SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Product approval and sustainable revenues
- ★ Important IP, innovative deal-making, acquisition
- ★ Involvement of one or more Swiss citizens
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Smart business strategy/joint venture
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland